<DOC>
	<DOC>NCT02497898</DOC>
	<brief_summary>The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.</brief_summary>
	<brief_title>Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>Autologous cytokine-induced killer (CIK) cells transfusion(&gt;2*10^9 cells count) within 2 weeks after regular chemotherapy every 3 months.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>diagnosed as nonHodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy patients refuse the therapy or have no tolerance for the therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>